V L Ng1, G E Sabla, H Melin-Aldana, N Kelley-Loughnane, J L Degen, J A Bezerra. 1. Divisions of Gastroenterology, Hepatology, and Nutrition, Children's Hospital Research Foundation and Department of Pediatrics, University of Cincinnati, Cincinnati, OH 45229-3039, USA.
Abstract
BACKGROUND/AIMS: Plasminogen directs matrix proteolysis during liver repair. Based on the role of hepatic stellate cells (HSCs) on matrix production, we investigated whether plasminogen-driven matrix proteolysis modulates the phenotype of HSCs. METHODS: Carbon tetrachloride was injected intraperitoneally into mice deficient in plasminogen, fibrinogen, or both, and to normal littermates, followed by determination of the phenotype of HSCs, matrix deposition, and apoptosis. RESULTS: Activation of HSCs was restricted to the zone of injury and increased >ten-fold above baseline regardless of the plasminogen status 2 days after toxin. Thereafter, the number of activated HSCs decreased to baseline levels between 7 and 14 days in normal mice, but remained elevated in plasminogen-deficient livers approximately ten-fold above non-targeted littermates. Despite the zonal increase in activated HSCs, the total number of desmin-stained HSCs was similar along the lobule in both genotypes. No appreciable difference in apoptosis of perisinusoidal cells was found between genotypes; however, fibrillary material was present in the subsinusoidal space of Plg(0) livers. This fibrillary material was not fibrin, as demonstrated by similar findings in Plg(0)/Fib(0) mice, which accumulated fibronectin in injured areas. CONCLUSIONS: Proteolytic clearance of non-fibrin matrix components by plasminogen must occur for HSCs to restore the quiescent phenotype during liver repair.
BACKGROUND/AIMS: Plasminogen directs matrix proteolysis during liver repair. Based on the role of hepatic stellate cells (HSCs) on matrix production, we investigated whether plasminogen-driven matrix proteolysis modulates the phenotype of HSCs. METHODS:Carbon tetrachloride was injected intraperitoneally into mice deficient in plasminogen, fibrinogen, or both, and to normal littermates, followed by determination of the phenotype of HSCs, matrix deposition, and apoptosis. RESULTS: Activation of HSCs was restricted to the zone of injury and increased >ten-fold above baseline regardless of the plasminogen status 2 days after toxin. Thereafter, the number of activated HSCs decreased to baseline levels between 7 and 14 days in normal mice, but remained elevated in plasminogen-deficient livers approximately ten-fold above non-targeted littermates. Despite the zonal increase in activated HSCs, the total number of desmin-stained HSCs was similar along the lobule in both genotypes. No appreciable difference in apoptosis of perisinusoidal cells was found between genotypes; however, fibrillary material was present in the subsinusoidal space of Plg(0) livers. This fibrillary material was not fibrin, as demonstrated by similar findings in Plg(0)/Fib(0) mice, which accumulated fibronectin in injured areas. CONCLUSIONS: Proteolytic clearance of non-fibrin matrix components by plasminogen must occur for HSCs to restore the quiescent phenotype during liver repair.
Authors: Kumar Shanmukhappa; Reena Mourya; Gregg E Sabla; Jay L Degen; Jorge A Bezerra Journal: Proc Natl Acad Sci U S A Date: 2005-07-08 Impact factor: 11.205
Authors: Akie Mochizuki; Aaron Pace; Cheryl E Rockwell; Katherine J Roth; Aaron Chow; Kate M O'Brien; Ryan Albee; Kara Kelly; Keara Towery; James P Luyendyk; Bryan L Copple Journal: J Immunol Date: 2014-03-17 Impact factor: 5.422
Authors: Aurelia Lugea; Li Nan; Samuel W French; Jorge A Bezerra; Anna S Gukovskaya; Stephen J Pandol Journal: Gastroenterology Date: 2006-09 Impact factor: 22.682
Authors: Harini Raghu; Alice Jone; Carolina Cruz; Cheryl L Rewerts; Malinda D Frederick; Sherry Thornton; Jay L Degen; Matthew J Flick Journal: Arthritis Rheumatol Date: 2014-06 Impact factor: 10.995
Authors: A A Higazi; M El-Haj; A Melhem; A Horani; O Pappo; C E Alvarez; N Muhanna; S L Friedman; R Safadi Journal: Clin Exp Immunol Date: 2008-02-14 Impact factor: 4.330